An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
Phase of Trial: Phase III
Latest Information Update: 12 Oct 2015
At a glance
- Drugs Ecopipam (Primary)
- Indications Self-injurious behaviour
- Focus Therapeutic Use
- Sponsors Psyadon Pharmaceuticals
- 06 Nov 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Oct 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2012-002662-12).
- 29 Jan 2013 New trial record